Nuvalent Inc (NUVL) Reports Q1, Highlights Pipeline Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. BAC
2. DPZ
3. NVDA
4. DRS
5. GS
6. JPM
7. ACI
8. ASML
9. ORCL
10. AVAV

Go back to Nuvalent Inc (NUVL) Reports Q1, Highlights Pipeline Progress

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

May 9, 2024 6:30 AM EDT

Updates from the ongoing Phase 1/2 ARROS-1 and ALKOVE-1 clinical trials expected at a medical meeting in the second half of 2024

Strong financial position with operating runway anticipated into 2027

CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today... More